Amy Comstock Rick, the new director of strategic coalitions for the FDA's Rare Disease Innovation Hub
Rare disease biopharma companies weigh in on FDA's new innovation hub
AstraZeneca’s Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
